Red flags and safety concerns

TL;DR — Four documented safety surfaces surround the FM label. (1) Diagnostic: guidelines frame FM diagnosis as clinical criteria plus exclusion of a somatic disease that sufficiently explains the symptoms via history, examination, and limited laboratory testing (Häuser 2015, PMID 27189527; Häuser & Fitzcharles 2018, PMID 29946212); where checked, the initial FM label was correct in only 34% of referrals — mostly over-diagnosis of other conditions as FM — while clinicians simultaneously miss ~half of criteria-positive patients (κ ≈ 0.3 diagnosed-vs-criteria; Fitzcharles 2003, PMID 12595620; Wolfe 2019, PMID 30724039; Srinivasan 2019, PMID 31777779). (2) Pharmacologic: opioid use runs at 11–69% of FM patients in claims data despite zero supporting RCT evidence and poorer observed outcomes; guidelines range from "reserve a weak-opioid trial for pain unresponsive to everything else, and discourage strong opioids" (Canada 2012) to "do not initiate opioids at all" (NICE NG193) (Nelli 2023, PMID 37535780; Gaskell 2016, PMID 27582266; Goldenberg 2016, PMID 26975749; Fitzcharles 2013, PMID 23748251; Carville 2021, PMID 33883123); gabapentinoid misuse and SNRI withdrawal are documented at scale, while the serotonergic-combination signal is strong in spontaneous reports and thin in criteria-confirmed cases. (3) Suicide: the only consistently elevated mortality signal in FM is suicide (pooled SMR 3.37), with unresolved mediation by psychiatric comorbidity (Treister-Goltzman 2023, PMID 37429737; Adawi 2021, PMID 34867495). (4) Market exposure: unvalidated commercial diagnostics, unproven interventions, and low-quality online information reach a patient population documented to rate non-evidence-based drugs as its most effective (Bennett 2007, PMID 17349056). No study yet tests whether structured red-flag screening or deprescribing changes any of these outcomes.

1. Features suggesting the diagnosis is not (only) fibromyalgia

FM produces diffuse pain, fatigue, and non-restorative sleep without objective inflammation, weakness, or structural progression. The mimic literature — review articles organized for chronic-widespread-pain workup — lists conditions whose presentations overlap FM and whose consequences of a missed diagnosis differ sharply: SLE, RA, ankylosing spondylitis, polymyalgia rheumatica, and osteoarthritis (Hwang & Barkhuizen 2006, PMID 16945247); inflammatory myopathy, joint hypermobility, osteomalacia and thyroid disease ("imminently treatable"), and infections that can mimic or trigger the syndrome (hepatitis C, Lyme disease, HIV, parvovirus) (Daoud & Barkhuizen 2002, PMID 12095463). Häuser and Fitzcharles add neurological and internal diseases (e.g., multiple myeloma) as excludable by careful clinical evaluation, and frame referral as warranted only on "reasonable clinical suspicion of some other condition" (PMID 29946212).

Feature at presentation	Points toward	Source (PMID)
Objective synovitis / joint swelling; radiographic change	RA, other inflammatory arthritis	16945247
Prolonged early-morning stiffness; limited lumbar mobility in >1 plane	Inflammatory arthritis / axSpA — both were significantly more common in the non-FM group among FM-labeled referrals	12595620
Inflammatory back pain phenotype without radiographic change	Non-radiographic axSpA (FM is a recognized confounder in this workup, in both directions)	35279103
New diffuse pain + elevated inflammatory markers in older adults	Polymyalgia rheumatica	16945247; 12095463
Proximal muscle weakness; elevated CK	Inflammatory myopathy	12095463
Myalgia on statin therapy	Statin-associated muscle symptoms — prevalence 7–29% in observational registries; true statin myopathy with significant CK elevation is rare (1/1,000–1/10,000 on standard doses)	25694464
Abnormal TSH	Thyroid disease	12095463
Bone pain / low vitamin D context	Osteomalacia; on the FM–vitamin D debate see below	12095463
Snoring, witnessed apneas, high OSA-questionnaire risk	Sleep-disordered breathing as a contributor to non-restorative sleep — in an FM treatment-program sample, 85.7% of STOP-BANG high-risk patients had abnormal overnight oximetry	31069165
Exposure/serologic context	Hepatitis C, Lyme, HIV, parvovirus	12095463

The vitamin D question is a documented unresolved debate rather than a clean red flag: FM/chronic-widespread-pain patients have lower serum 25-OH-D than controls (SMD −0.56; Makrani 2017, PMID 29123619) and higher odds of hypovitaminosis D (crude OR 1.63, adjusted 1.41; Hsiao 2015, PMID 26431141), and a 4-RCT meta-analysis found a small pain reduction with supplementation (VAS MD 0.46) that did not track the achieved serum change (Yong 2017, PMID 28812209) — association is reproducible, causation and treatment relevance are not established.

Two structural caveats. First, since the 2016 criteria removed the exclusion clause, FM is diagnosable alongside other diseases (see diagnostic-criteria) — and concomitant FM is common in inflammatory disease (pooled 21% in RA, 13% in AS, 18% in PsA), where it inflates the patient-reported components of disease-activity scores (DAS28 +1.24 in RA, BASDAI +2.22 in AS; Duffield 2018, PMID 29788461). "Not (only) FM" therefore cuts both ways: an FM-labeled patient may have a missed inflammatory disease, and an inflammatory-disease patient may have unrecognized FM driving apparent refractoriness (comorbidities-and-overlap).

Second, the documented misdiagnosis base rates run in both directions simultaneously. In the one prospective referral audit, the initial FM label survived rheumatologic evaluation in only 34% of cases, with error "mostly... overdiagnosis" of other rheumatic conditions as FM (Fitzcharles 2003, PMID 12595620). In a university clinic, physicians missed 49.6% of criteria-positive patients and labeled 11.4% of criteria-negative ones (κ = 0.41 overall, 0.32 within RA; Wolfe 2019, PMID 30724039); in primary care, agreement was κ = 0.296, with only 32.2% of physician-diagnosed FM meeting criteria (Srinivasan 2019, PMID 31777779). The full over/under-diagnosis evidence table lives in diagnostic-criteria; the safety-relevant corollary is that every FM-labeled population contains a minority with a different, potentially progressive disease, and every criteria-positive population contains a majority without the label or its management.

A note on what guidelines actually specify. The German AWMF S3 guideline (number 145/004, 2017 update, developed by 13 scientific societies and 2 patient organisations) sets the clinical diagnosis by the ACR 1990 classification criteria with tender-point examination or by the modified preliminary ACR 2010/2011 criteria without it (Eich 2017, PMID 28421273); the item-level red-flag list in its diagnostic algorithm is not reproduced in the indexed record, so the table above is assembled from the mimic literature rather than transcribed from a guideline checklist.

2. Re-evaluation triggers

The literature on when to revisit an established FM label is thin; what is documented:

• Features that discriminated in the referral audit — prolonged morning stiffness and objective limitation of spinal mobility marked the mislabeled (non-FM) patients (Fitzcharles 2003, PMID 12595620). Their appearance in a previously typical FM course is the empirically grounded trigger.
• Objective findings over subjective intensification. In inflammatory-disease cohorts with concomitant FM, the FM-inflated score components are the subjective ones (tender joint count, patient VAS), not objective measures (Duffield 2018, PMID 29788461) — the reverse implication for an FM-labeled patient is that new objective findings (synovitis, weakness, CK, inflammatory markers), not symptom intensity per se, are what warrant re-workup. In nr-axSpA the differentiation depends on recognizing disease-specific clinical features rather than symptom burden (Mease & Deodhar 2022, PMID 35279103).
• Against serial re-investigation. Guidelines position the FM diagnosis itself as the brake on repeat testing: communicating the label is intended to "reduce repeated unnecessary diagnostic procedures and inappropriate drug treatments," with specialist referral reserved for reasonable clinical suspicion (Häuser & Fitzcharles 2018, PMID 29946212). The economic footprint is measured: after a coded FM diagnosis in UK primary care, costs fell £66.21/patient/6 months below the pre-diagnosis trend, led by reductions in tests and imaging (Annemans 2008, PMID 18311794) — i.e., the pre-diagnosis state is one of ongoing serial investigation.
• The boundary of this section. No study was located that quantifies the diagnostic yield, optimal interval, or outcome effect of structured re-assessment of established FM labels. Statements circulating about marked asymmetry or progressive course as specific re-evaluation triggers are clinical inference from the mimic literature; no source verified here tests them as a protocol, and they are not stated as such above.

3. Medication safety signals

Efficacy numbers live in pharmacologic-therapy; this section is the harm-and-exposure ledger.

Opioids

• Evidence base: empty. The Cochrane review of oxycodone for FM found zero eligible RCTs (Gaskell 2016, PMID 27582266); a MEDLINE/Cochrane review found "no evidence from clinical trials that opioids are effective" in FM, observational data showing opioid users with poorer outcomes than non-users, and guidelines recommending against opioid analgesics (Goldenberg 2016, PMID 26975749). Guideline positions differ in a way worth stating precisely rather than collapsing into "guidelines say no". The 2012 Canadian guideline does not ban opioids: recommendation 29 holds that "a trial of opioids, beginning with a weak opioid, such as tramadol, should be reserved for treatment of patients with moderate to severe pain that is unresponsive to other treatment modalities" (level 2, grade D), and recommendation 30 that "strong opioid use is discouraged," with continued users required to demonstrate improved pain and function under monitoring for aberrant drug behaviour (level 5, grade D) (Fitzcharles 2013, PMID 23748251). EULAR's 2017 revision does not single opioids out but places every pharmacological option at 'weak for', with exercise the only 'strong for' recommendation in the guideline (Macfarlane 2017, PMID 27377815). NICE goes furthest: recommendation 1.2.10 of NG193 directs clinicians not to initiate opioids for chronic primary pain in people aged 16 and over — in the same list as gabapentinoids and other antiepileptics, antipsychotics, benzodiazepines, NSAIDs and paracetamol; antidepressants are the only pharmacological class it offers (Carville 2021, PMID 33883123; NICE — "Chronic pain (primary and secondary) in over 16s: assessment of all chronic pain and management of chronic primary pain", NG193, https://www.nice.org.uk/guidance/ng193/chapter/Recommendations, accessed 2026-08-31). The recommendation governs initiation; managing people already established on these drugs is handled separately. See guidelines.
• Exposure: large anyway. Health-claims studies report opioid use in 11.3–69% of FM patients (range cited in Nelli 2023, PMID 37535780). In a Canadian tertiary-care FM clinic, 32% of 457 referred patients used opioids, over two-thirds of them strong opioids; use was associated with lower education, unemployment, disability payments, current unstable psychiatric disorder, substance-abuse history, and prior suicide attempts (Fitzcharles 2011, PMID 21962316). Among US insured FM patients ≥65 initiating pregabalin, opioids were the most-prescribed drug class (54.1% pre-index, 59.2% post-index), and opioid+antidepressant combinations ran at 35% (Gore 2010, PMID 20586523).
• Perception gap. Patients rank hydrocodone and oxycodone preparations among their most effective drugs (Bennett 2007, PMID 17349056) — the exposure is preference-sustained, not merely prescriber inertia (patient-experience-and-advocacy).

Benzodiazepines

Alprazolam and clonazepam also appear among patients' perceived-most-effective medications (Bennett 2007, PMID 17349056), and benzodiazepine-class drug use distinguished FM from non-FM women in a community survey (Shaver 2009, PMID 19445618); no RCT evidence supporting benzodiazepines for core FM symptoms was located this session, and NICE NG193 rec 1.2.10 places benzodiazepines on its do-not-initiate list for chronic primary pain (Carville 2021, PMID 33883123). FM-specific benzodiazepine harm data — falls, dependence, cognitive effects measured in this population rather than extrapolated from older or mixed chronic-pain cohorts — were not located this session. This is an evidence gap, not a safety clearance.

Serotonin syndrome and tramadol

The common FM regimens (SNRI, TCA, tramadol, SSRI) are the drug classes that dominate serotonin-syndrome pharmacovigilance: in 125 criteria-confirmed French cases, antidepressants were the most-involved drugs, opioids (mainly tramadol) were involved in 14.8%, and the most frequent pharmacodynamic interaction was SRI + opioid — typically paroxetine + tramadol; 40.8% of cases involved a single serotonergic drug at normal dose (Abadie 2015, PMID 26082973). Evidence quality note: these are spontaneous-report data, not FM cohorts. A countervailing clinical-toxicology series found no Hunter-criteria serotonin toxicity in 71 tramadol overdoses — but dose-related seizures (8/71) and respiratory depression (13/71) (Ryan & Isbister 2015, PMID 25901965); the seizure/respiratory signal is better documented than the serotonin one for tramadol alone.

SNRI/SSRI + triptan is the interaction FM patients with comorbid migraine actually meet, and it is weaker than the warning implies. The FDA issued a July 2006 alert on potentially life-threatening serotonin syndrome from combined SSRI/SNRI and triptan use. When the 29 case reports underlying that alert were obtained under a Freedom of Information Act request and scored against formal criteria, 7 met the Sternbach criteria, none met the Hunter criteria, and none met both; the author's conclusion was that the combination might rarely precipitate serotonin syndrome but that "the data do not support prohibiting the use of triptans with SSRIs or SNRIs" (Evans 2007, PMID 18092054). The 2010 American Headache Society position paper likewise found the information conflicting and insufficient, classing it Level U and declining to limit co-prescribing while cautioning that monitoring is warranted; co-prescribing meanwhile rose 90.1% between 2003–04 and 2007–08, reaching 1.8% of the relevant patient population, and the number of resulting serotonin-syndrome cases remains undocumented (Sclar 2012, PMID 22289074). The pattern across all three sources on this page — Abadie, Ryan & Isbister, Evans — is the same: the pharmacovigilance signal is real at the level of spontaneous reports and thin at the level of criteria-confirmed events.

Gabapentinoids

• Misuse/abuse: the updated systematic review (55 studies) concludes gabapentinoid misuse is a growing trend causing significant patient harm — increased hospital utilization and opioid-overdose mortality risk — with opioid use disorder the greatest risk factor for gabapentinoid abuse (Evoy 2021, PMID 33215352). The systematic review of 14 clinical-epidemiologic studies and 38 case reports/series found that misuse clusters in people with other substance dependencies — primarily opiate dependence and polyvalent use — that only 4 identified individuals met behavioural dependence criteria without another substance use disorder (all on pregabalin), and that drug users prefer pregabalin to oral gabapentin, citing faster and stronger euphoria; tolerance and withdrawal appeared common in both medical and non-medical use (Bonnet & Scherbaum 2017, PMID 29179227).
• Sedation and driving: in the FM Cochrane review, dizziness NNH 3.7 and somnolence NNH 7.4 (all doses combined; weight gain 18 and peripheral oedema 19), with 70–90% of participants in all arms — placebo included — reporting ≥1 adverse event, and withdrawals for adverse events about 10 percentage points higher on pregabalin than placebo (Derry 2016, PMID 27684492). The only driving-simulator study located (healthy volunteers, 75 mg doses) found no overt impairment but abolished the training-related improvement seen under placebo (Tujii 2014, PMID 24501544) — low-dose, non-patient data; the FM-relevant driving question is untested.

Discontinuation phenomena

Withdrawal symptoms occur after discontinuation of every SNRI (the FM-relevant drugs duloxetine and milnacipran included), typically starting within days and lasting weeks, even with gradual tapering, with late-onset and persistent variants documented (systematic review of 61 reports; Fava 2018, PMID 30016772). Given ~50–65% real-world discontinuation of FM drugs within a year (pharmacologic-therapy), withdrawal phenomena are a population-scale exposure, and can mimic relapse.

Polypharmacy

Community FM women reported taking on average 4.6 concurrent medications vs 1.4 in non-FM controls (93% vs 56% taking ≥1), spanning antidepressants, anticonvulsants, muscle relaxants, opioids, NSAIDs, and benzodiazepines (Shaver 2009, PMID 19445618); in the older insured cohort the combination burden was similar (Gore 2010, PMID 20586523). CNS-active polypharmacy is thus the default treated state, while combination efficacy evidence is nearly absent (pharmacologic-therapy).

4. The suicide-risk signal

All-cause mortality in FM is at most mildly elevated and null in criteria-defined subgroups (epidemiology); the cause-specific exception is suicide, replicated across designs:

Estimate	Population	Source (PMID)
Suicide SMR 3.37 (95% CI 1.52–7.50); also infections SMR 1.66, accidents borderline 1.95	Meta-analysis, 8 studies, 188,751 patients	37429737
Suicide OR 3.31 (2.15–5.11); accidental death OR 1.45	8,186 US patients, 35 years	20662040
Suicide SMR 10.5 (4.5–20.7) in women; elevated at diagnosis and after 5 years; no excess in the 84 men	1,361 Danish referred patients	20583101
Suicidal ideation prevalence 29.57% (95% CI 1.84–72.07), OR 9.12; attempts 5.69%, OR 3.12; suicide events HR 1.38	Meta-analysis, 13 studies, 394,087 patients	34867495

The mediation question is explicitly unresolved: determinants include depression, anxiety, poor sleep, and pain severity, and in some adjusted analyses the association loses statistical significance after accounting for psychiatric comorbidity — against a background of high heterogeneity and publication-bias evidence (Adawi 2021, PMID 34867495). The Danish authors attribute the excess to lifetime psychiatric comorbidity and state that suicide risk factors "should be sought at the time of the diagnosis of FM and at followup" (Dreyer 2010, PMID 20583101); the mortality meta-analysis draws the same system-level conclusion — screening for suicidal ideation as part of FM care (Treister-Goltzman 2023, PMID 37429737). Guidelines converge here: interdisciplinary FM guidelines recommend screening for psychological distress and referral to mental health care for comorbid mental disorder (Häuser & Fitzcharles 2018, PMID 29946212). Whether any FM-directed intervention lowers suicide risk is untested (epidemiology, comorbidities-and-overlap).

5. Exploitation and misinformation exposure

A stigmatized condition with no objective test, modest drug effects, and a 2–6-year diagnostic delay is a structurally attractive market for unvalidated products; the documented pieces:

• Unvalidated commercial diagnostics. The cytokine-stimulation study underlying the commercially marketed FM/a blood test reported lower mitogen-stimulated cytokine production in 110 FM patients vs 91 controls and proposed the assay as "a diagnostic methodology" (Behm 2012, PMID 23245186); why this falls short of a validated diagnostic — case-control design, no criteria-blinded validation, no demonstrated separation from other pain conditions — is analyzed in biomarkers. No biomarker test for FM has achieved validated diagnostic status (biomarkers).
• Unproven interventions with documented uptake. Guaifenesin — the centerpiece of a popular protocol — showed 11.5% ever-use among FM clinic patients (CAM ever-use 92.6% overall; Wall 2007, PMID 25170357) and was among the drugs patients rated most effective in a community survey (Shaver 2009, PMID 19445618); no RCT evidence supporting it was located this session. A PubMed search for guaifenesin and fibromyalgia returns three records, none of them a trial of guaifenesin; the widely cited negative 1-year double-blind study appears to be conference-published and has no PubMed record, so it is named here as an absence rather than cited as a source. Cannabis clinics illustrate the supply side: 29 Ontario clinic websites promoted cannabis for indications including fibromyalgia, citing evidence of which 15.3% was lowest-level, with only 4 sites mentioning any harms (O'Neill 2023, PMID 37384372).
• Online information quality. Across 161 chronic-pain websites (fibromyalgia among the five search terms), mean DISCERN quality was 55.9/80 with mean readability at US grade 10.9 — above most patients' reading level — and commercial product sales present on a subset (Kaicker 2010, PMID 20939875). On YouTube, 86.7% of non-medical uploaders' FM exercise videos were low quality, and 93.7% of patient-targeted videos were low-to-medium quality (Zure 2023, PMID 37845414). This meets a patient population that organizes and informs itself substantially online (the largest FM patient survey was itself internet-based via the National Fibromyalgia Association; Bennett 2007, PMID 17349056) — see patient-experience-and-advocacy for the demand-side context of legitimacy-seeking.

Open questions

• Does structured red-flag screening at the point of FM diagnosis change outcomes (missed-mimic rate, time-to-correct-diagnosis, cost)? The misdiagnosis base rates are quantified (PMID 12595620; PMID 31777779) but no screening-strategy trial exists.
• Can deprescribing programs (opioids, benzodiazepines, gabapentinoids) work in FM specifically? Exposure is documented at scale (PMID 37535780; PMID 21962316; PMID 33215352) with no FM-specific deprescribing trial located.
• Is the suicide excess modifiable by FM treatment, or fully mediated by psychiatric comorbidity? Adjusted analyses are inconsistent (PMID 34867495; PMID 37429737).
• What re-evaluation interval and trigger set for an established FM label maximizes mimic detection without re-igniting serial over-investigation? The two costs pull in opposite directions (PMID 12595620 vs PMID 18311794) and no study optimizes the trade-off.
• Does regulation or labeling of unvalidated commercial diagnostics measurably change patient exposure or spending? Uptake-side data exist for unproven therapies (PMID 25170357) but not for diagnostics.

Related pages

• diagnostic-criteria — the κ ≈ 0.3 diagnosed-vs-criteria divide and the full over/under-diagnosis evidence.
• pharmacologic-therapy — efficacy/NNT side of every drug named here; what fails (opioids, NSAIDs).
• comorbidities-and-overlap — concomitant FM in inflammatory disease; psychiatric comorbidity behind the suicide signal.
• epidemiology — mortality and suicide statistics in full; diagnostic delay.
• biomarkers — why no blood test (FM/a included) is validated for diagnosis.
• guidelines — the guideline texts whose recommendations (against opioids; for mental-health screening) anchor this page.
• patient-experience-and-advocacy — the demand side of misinformation exposure and the trial-vs-lived-treatment gap.

References

1. Hwang E, Barkhuizen A. Update on rheumatologic mimics of fibromyalgia. Curr Pain Headache Rep. 2006;10(5):327-32. PMID 16945247
2. Daoud KF, Barkhuizen A. Rheumatic mimics and selected triggers of fibromyalgia. Curr Pain Headache Rep. 2002;6(4):284-8. PMID 12095463
3. Mease P, Deodhar A. Differentiating nonradiographic axial spondyloarthritis from its mimics: a narrative review. BMC Musculoskelet Disord. 2022;23(1):240. PMID 35279103
4. Fitzcharles MA, Boulos P. Inaccuracy in the diagnosis of fibromyalgia syndrome: analysis of referrals. Rheumatology (Oxford). 2003;42(2):263-7. PMID 12595620
5. Wolfe F, et al. Diagnosis of Fibromyalgia: Disagreement Between Fibromyalgia Criteria and Clinician-Based Fibromyalgia Diagnosis in a University Clinic. Arthritis Care Res (Hoboken). 2019;71(3):343-351. PMID 30724039
6. Srinivasan S, et al. The Problematic Nature of Fibromyalgia Diagnosis in the Community. ACR Open Rheumatol. 2019;1(1):43-51. PMID 31777779
7. Häuser W, Fitzcharles MA. Facts and myths pertaining to fibromyalgia. Dialogues Clin Neurosci. 2018;20(1):53-62. PMID 29946212
8. Häuser W, et al. Fibromyalgia. Nat Rev Dis Primers. 2015;1:15022. PMID 27189527
9. Duffield SJ, et al. Concomitant fibromyalgia complicating chronic inflammatory arthritis: a systematic review and meta-analysis. Rheumatology (Oxford). 2018;57(8):1453-1460. PMID 29788461
10. Stroes ES, et al. Statin-associated muscle symptoms: impact on statin therapy — European Atherosclerosis Society Consensus Panel Statement on Assessment, Aetiology and Management. Eur Heart J. 2015;36(17):1012-22. PMID 25694464
11. Hsiao MY, et al. Is Serum Hypovitaminosis D Associated with Chronic Widespread Pain Including Fibromyalgia? A Meta-analysis of Observational Studies. Pain Physician. 2015;18(5):E877-87. PMID 26431141
12. Makrani AH, et al. Vitamin D and fibromyalgia: a meta-analysis. Korean J Pain. 2017;30(4):250-257. PMID 29123619
13. Yong WC, Sanguankeo A, Upala S. Effect of vitamin D supplementation in chronic widespread pain: a systematic review and meta-analysis. Clin Rheumatol. 2017;36(12):2825-2833. PMID 28812209
14. Clark SD, et al. Utilization of Overnight Pulse Oximetry in Fibromyalgia Patients. Glob Adv Health Med. 2019;8:2164956119847125. PMID 31069165
15. Annemans L, et al. Health economic consequences related to the diagnosis of fibromyalgia syndrome. Arthritis Rheum. 2008;58(3):895-902. PMID 18311794
16. Goldenberg DL, Clauw DJ, Palmer RE, Clair AG. Opioid Use in Fibromyalgia: A Cautionary Tale. Mayo Clin Proc. 2016;91(5):640-8. PMID 26975749
17. Gaskell H, Moore RA, Derry S, Stannard C. Oxycodone for pain in fibromyalgia in adults. Cochrane Database Syst Rev. 2016;9(9):CD012329. PMID 27582266
18. Fitzcharles MA, Ste-Marie PA, Gamsa A, Ware MA, Shir Y. Opioid use, misuse, and abuse in patients labeled as fibromyalgia. Am J Med. 2011;124(10):955-60. PMID 21962316
19. Nelli A, Wright MC, Gulur P. Green Light-Based Analgesia — Novel Nonpharmacological Approach to Fibromyalgia Pain: A Pilot Study. Pain Physician. 2023;26(4):403-410. PMID 37535780
20. Gore M, Sadosky A, Zlateva G, Clauw D. Initial use of pregabalin, patterns of pain-related pharmacotherapy, and healthcare resource use among older patients with fibromyalgia. Am J Manag Care. 2010;16(5 Suppl):S144-53. PMID 20586523
21. Fitzcharles MA, et al. 2012 Canadian Guidelines for the diagnosis and management of fibromyalgia syndrome: executive summary. Pain Res Manag. 2013;18(3):119-26. PMID 23748251
22. Macfarlane GJ, et al. EULAR revised recommendations for the management of fibromyalgia. Ann Rheum Dis. 2017;76(2):318-328. PMID 27377815
23. Carville S, Constanti M, Kosky N, Stannard C, Wilkinson C. Chronic pain (primary and secondary) in over 16s: summary of NICE guidance. BMJ. 2021;373:n895. PMID 33883123
24. Bennett RM, Jones J, Turk DC, Russell IJ, Matallana L. An internet survey of 2,596 people with fibromyalgia. BMC Musculoskelet Disord. 2007;8:27. PMID 17349056
25. Abadie D, et al. Serotonin Syndrome: Analysis of Cases Registered in the French Pharmacovigilance Database. J Clin Psychopharmacol. 2015;35(4):382-8. PMID 26082973
26. Ryan NM, Isbister GK. Tramadol overdose causes seizures and respiratory depression but serotonin toxicity appears unlikely. Clin Toxicol (Phila). 2015;53(6):545-50. PMID 25901965
27. Evoy KE, et al. Abuse and Misuse of Pregabalin and Gabapentin: A Systematic Review Update. Drugs. 2021;81(1):125-156. PMID 33215352
28. Bonnet U, Scherbaum N. [On the risk of dependence on gabapentinoids]. Fortschr Neurol Psychiatr. 2018;86(2):82-105. PMID 29179227
29. Fava GA, et al. Withdrawal Symptoms after Serotonin-Noradrenaline Reuptake Inhibitor Discontinuation: Systematic Review. Psychother Psychosom. 2018;87(4):195-203. PMID 30016772
30. Derry S, et al. Pregabalin for pain in fibromyalgia in adults. Cochrane Database Syst Rev. 2016;9(9):CD011790. PMID 27684492
31. Tujii T, et al. Evaluation of the effect of pregabalin on simulated driving ability using a driving simulator in healthy male volunteers. Int J Gen Med. 2014;7:103-8. PMID 24501544
32. Shaver JL, Wilbur J, Lee H, Robinson FP, Wang E. Self-reported medication and herb/supplement use by women with and without fibromyalgia. J Womens Health (Larchmt). 2009;18(5):709-16. PMID 19445618
33. Adawi M, et al. Suicidal Behavior in Fibromyalgia Patients: Rates and Determinants of Suicide Ideation, Risk, Suicide, and Suicidal Attempts — A Systematic Review of the Literature and Meta-Analysis of Over 390,000 Fibromyalgia Patients. Front Psychiatry. 2021;12:629417. PMID 34867495
34. Treister-Goltzman Y, Peleg R. Fibromyalgia and mortality: a systematic review and meta-analysis. RMD Open. 2023;9(3):e003005. PMID 37429737
35. Dreyer L, et al. Mortality in a cohort of Danish patients with fibromyalgia: increased frequency of suicide. Arthritis Rheum. 2010;62(10):3101-8. PMID 20583101
36. Wolfe F, Hassett AL, Walitt B, Michaud K. Mortality in fibromyalgia: a study of 8,186 patients over thirty-five years. Arthritis Care Res (Hoboken). 2011;63(1):94-101. PMID 20662040
37. Behm FG, et al. Unique immunologic patterns in fibromyalgia. BMC Clin Pathol. 2012;12:25. PMID 23245186
38. Wall GC, Krypel LL, Miller MJ, Rees DM. A pilot study of complementary and alternative medicine use in patients with fibromyalgia syndrome. Pharm Pract (Granada). 2007;5(4):185-90. PMID 25170357
39. Kaicker J, Borg Debono V, Dang W, Buckley N, Thabane L. Assessment of the quality and variability of health information on chronic pain websites using the DISCERN instrument. BMC Med. 2010;8:59. PMID 20939875
40. Zure M, Korkmaz MD, Menekşeoğlu AK. Exercises for fibromyalgia syndrome: what YouTube tells us as a source of information for patient and physician education. Clin Rheumatol. 2024;43(1):473-480. PMID 37845414
41. O'Neill B, et al. Evaluating the Supporting Evidence of Medical Cannabis Claims Made on Clinic Websites: Cross-Sectional Study. J Med Internet Res. 2023;25:e45550. PMID 37384372
42. Eich W, Bär KJ, Bernateck M, et al. [Definition, classification, clinical diagnosis and prognosis of fibromyalgia syndrome: Updated guidelines 2017 and overview of systematic review articles]. Schmerz. 2017;31(3):231-238. PMID 28421273
43. Evans RW. The FDA alert on serotonin syndrome with combined use of SSRIs or SNRIs and triptans: an analysis of the 29 case reports. MedGenMed. 2007;9(3):48. PMID 18092054
44. Sclar DA, Robison LM, Castillo LV, Schmidt JM. Concomitant use of triptan, and SSRI or SNRI after the US Food and Drug Administration alert on serotonin syndrome. Headache. 2012;52(2):198-203. PMID 22289074
45. National Institute for Health and Care Excellence — "Chronic pain (primary and secondary) in over 16s: assessment of all chronic pain and management of chronic primary pain" (NG193), https://www.nice.org.uk/guidance/ng193/chapter/Recommendations, accessed 2026-08-31

---

This is a research knowledge base, not medical advice. Content describes published evidence and guideline statements; it is not a basis for individual clinical decisions.